Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer

This is a multicenter，randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)

Trial Details

NCT ID
NCT06128837
Phase
PHASE3
Sponsor
Luye Pharma Group Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Irinotecan hydrochloride liposome Injection
  • Topotecan
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age ≥ 18 years, male or female;
  • Patients with histologically and/or cytologically confirmed small cell lung cancer;
  • Disease progression (CTFI ≥ 30 days and ≤ 6 months) occurred after at least 4 cycles of first-line etoposide + platinum two-drug chemotherapy-based…
  • At least one evaluable lesion (according to RECIST 1.1 criteria);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →